Krishnansu S. Tewari, MD of University of California, Irvine gives an overview of the FOCUS trial, which is sponsored by Mateon Therapeutics in South San Francisco, CA. The FOCUS trial is a double-blind, randomized, phase 2/3 clinical study evaluating the efficacy and safety of physicians choice chemotherapy plus bevacizumab and CA4P versus physicians choice chemotherapy plus bevacizumab and placebo in patients with platinum-resistant ovarian cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL
FOCUS Trial: CA4P in Patients with Platinum Resistant Ovarian Cancer
